Targeted drugs in combination with radiotherapy for the treatment of solid tumors: Current state and future developments

Expert Review of Clinical Pharmacology

Volumn 6, Issue 6, 2013, Pages 663-676

  Selzer, Edgar ^a   Kornek, Gabriela ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

clinical study; radiation oncology; solid tumor; targeted drugs

Indexed keywords

ABIRATERONE ACETATE; ADCRETRIS; AFLIBERCEPT; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; BORTEZOMIB; BOSUTINIB; CABOZANTINIB; CARBOPLATIN; CARFILZOMIB; CATUMAXOMAB; CETUXIMAB; CISPLATIN; CRIZOTINIB; DASATINIB; DEGARELIX; DENOSUMAB; ENZALUTAMIDE; ERLOTINIB; EVEROLIMUS; GEFITINIB; GEMTUZUMAB OZOGAMICIN; IMATINIB; IPILIMUMAB; LAPATINIB; NILOTINIB; OFATUMUMAB; PACLITAXEL; PANITUMUMAB; PAZOPANIB; PERTUZUMAB; PONATINIB; PRALATREXATE; REGORAFENIB; RITUXIMAB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; TRAMETINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VEMURAFENIB; VISMODEGIB; VORINOSTAT;

ANTIANGIOGENIC ACTIVITY; ANUS CANCER; BRAIN METASTASIS; BRAIN TUMOR; BREAST CANCER; CANCER RADIOTHERAPY; CHORDOMA; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; DRUG TARGETING; ENDOMETRIUM CANCER; ENDOTHELIUM CELL; ESOPHAGUS CANCER; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; NAUSEA; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; PROSTATE CANCER; RADIOSENSITIVITY; RECTUM CANCER; REVIEW; SALIVARY GLAND TUMOR; SKIN CANCER; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; THYROID CANCER; TUMOR GROWTH; UTERINE CERVIX CANCER; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; RADIOTHERAPY;

EID: 84887276545     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2013.841540     Document Type: Review

References (86)

1. Hebar A, Valent P, Selzer E. The impact of molecular targets in cancer drug development: major hurdles and future strategies. Expert Rev. Clin. Pharmacol. 6(1), 23-34 (2013).
2. Kornek G, Selzer E. Targeted therapies in solid tumours: pinpointing the tumour's Achilles heel. Curr. Pharm. 15(2), 207-42 Review (2009).
3. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362, 847-849 (1993).
4. McKenna WG, Muschel RJ, Gupta AK, Hahn SM, Bernhard EJ. The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene 22(37), 5866-5875 Review (2003).
5. Raben D, Helfrich B. Angiogenesis inhibitors: a rational strategy for radiosensitization in the treatment of non-small-cell lung cancer? Clin. Lung Cancer 6(1), 48-57 Review (2004).
6. Raben D, Helfrich B, Bunn PA Jr. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective. Int. J. Radiat. Oncol. Biol. Phys. 59(2 Suppl.), 27-38 Review (2004).
7. Raben D, Bianco C, Helfrich B, Weng E, Ciardiello F, Harari P. Interference with EGFR signaling: paradigm for improving radiation response in cancer treatment. Expert Rev. Anticancer Ther. 2(4), 461-471 Review (2002).
8. Ang KK, Sturgis EM. Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. Semin. Radiat. Oncol. 22(2), 128-142 Review (2012).
9. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 11(8), 781-789 (2010).
10. Chung C, Christianson M. Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: A systemic review of current development, evidence, and recommendation. J. Oncol. Pharm. Pract. (2013) (Epub ahead of print).
11. Kasper S, Breitenbuecher F, Reis H et al. Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade. Oncogene 32(23), 2873-2881 (2013).
12. Choi EJ, Ryu YK, Kim SY et al. Targeting epidermal growth factor receptor-associated signaling pathways in non-small cell lung cancer cells: implication in radiation response. Mol. Cancer Res. 8(7), 1027-1036 (2010).
13. Toulany M, Kasten-Pisula U, Brammer I et al. Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. Clin. Cancer Res. 12(13), 4119-4126 (2006).
14. Koh PK, Faivre-Finn C, Blackhall FH, De Ruysscher D. Targeted agents in non-small cell lung cancer (NSCLC): clinical developments and rationale for the combination with thoracic radiotherapy. Cancer Treat. Rev. 38(6), 626-640 (2012).
15. Bourhis J, Lefebvre JL, Vermorken JB. Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options? Eur. J. Cancer 46, 1979-1989 (2010).
16. Specenier P, Vermorken JB. Cetuximab: its unique place in head and neck cancer treatment. Biologics 7, 77-90 (2013).
17. Magné N, Chargari C, Castadot P et al. The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials. Eur. J. Cancer. 44(15), 2133-2143 (2008).
18. Martins RG, Parvathaneni U, Bauman JE et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. J. Clin. Oncol. 31(11), 1415-1421 (2013).
19. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 11, 21-28 (2010).
20. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567-578 (2006).
21. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359(11), 1116-1127 (2008).
22. Pfister DG, Ang KK, Brizel DM et al.; National Comprehensive Concer Network. Head and neck cancers. J. Natl. Compr. Canc. Netw. 9(6), 596-650 (2011).
23. Vincenzi B, Zoccoli A, Pantano F, Venditti O, Galluzzo S. Cetuximab: from bench to bedside. Curr. Cancer Drug Targets 10(1), 80-95 (2010).
24. Giralt J, Fortin A, Mesia R et al. A Phase 2, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). J. Clin. Oncol. 30(Suppl.), abstract 5502 (2007).
25. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group. J. Clin. Oncol. 25, 1960-1966 (2007).
26. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2):123-132 (2005).
27. Martins RG, Parvathaneni U, Bauman JE et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. J. Clin. Oncol. 31(11), 1415-1421 (2013).
28. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).
29. Folkman J. Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 285(21), 1182-1186 (1971).
30. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2(10), 795-803 (2002).
31. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med. 17(11), 1359-1370 (2011).
32. Ostergaard L, Tietze A, Nielsen T et al. The relationship between tumor blood flow, angiogenesis, tumor hypoxia, and aerobic glycolysis. Cancer Res. doi:10.1158/0008-5472. CAN-13-0964 (2013) (Epub ahead of print).
33. Garcia-Barros M, Paris F, Cordon-Cardo C et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300(5622), 1155-1159 (2003).
34. Folkman J, Camphausen K. Cancer. What does radiotherapy do to endothelial cells? Science 293(5528), 227-228 (2001).
35. Tremoulet AH, Albani S. Novel therapies for rheumatoid arthritis. Expert Opin. Investig. Drugs 15(11), 1427-1441 (2006).
36. Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin. Cancer Res. 9, 1957-1971 Review (2003).
37. Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res. 66, 11520-11539 (2006).
38. Qiu W, Leibowitz B, Zhang L, Yu J. Growth factors protect intestinal stem cells from radiation-induced apoptosis by suppressing PUMA through the PI3K/AKT/ p53 axis. Oncogene 29(11), 1622-1632 (2010).
39. Paris F, Fuks Z, Kang A et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293, 293-297 (2001).
40. El Kaffas A, Giles A, Czarnota GJ. Dose-dependent response of tumor vasculature to radiation therapy in combination with Sunitinib depicted by three-dimensional high-frequency power Doppler ultrasound. Angiogenesis 16, 443-454 (2013).
41. Gomes FG, Nedel F, Alves AM, Nör JE, Tarquinio SB. Tumor angiogenesis and lymphangiogenesis: tumor/endothelial crosstalk and cellular/microenvironmental signaling mechanisms. Life Sci. 92, 101-107 (2013).
42. Avraamides, CJ, Garmy-Susini B, Varner J. Integrins in angiogenesis and lymphangiogenesis. Nat. Rev. Cancer 8, 604-617 (2008).
43. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 15, 232-239 (2009).
44. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 8, 210-221 (2011).
45. Conley SJ, Gheordunescu E, Kakarala P et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc. Natl. Acad. Sci. U.S.A. 109, 2784-2789 (2012).
46. Relf M, LeJeune S, Scott PA et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57(5), 963-969 (1997).
47. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J. Clin. Oncol. 19(4), 1207-1225 (2001).
48. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors - impact on future treatment strategies. Nat. Rev. Clin. Oncol. 7(9), 493-507 (2010).
49. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol. Cancer Res. 5(3), 203-220 (2007).
50. Amin DN, Hida K, Bielenberg DR, Klagsbrun M. Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res. 66(4), 2173-2180 (2006).
51. Perrotte P, Matsumoto T, Inoue K et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 5(2), 257-265 (1999).
52. Pueyo G, Mesia R, Figueras A et al. Cetuximab may inhibit tumor growth and angiogenesis induced by ionizing radiation: a preclinical rationale for maintenance treatment after radiotherapy. Oncologist 15(9), 976-986 (2010).
53. Amin DN, Bielenberg DR, Lifshits E, Heymach JV, Klagsbrun M. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells. Microvasc. Res. 76(1), 15-22 (2008).
54. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 9, 9-22 (2010).
55. Jin H, Varner J. Integrins: Roles in cancer development and as treatment agents. Br. J. Cancer 90, 561-565 (2004).
56. Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat. Rev. Drug Discov. 9, 804-820 (2010).
57. Minton K. Cell adhesion: Integrating the integrin response. Nat. Rev. Mol. Cell Biol. 14(7), 401 (2013).
58. Gingras MC, Roussel E, Bruner JM, Branch CD, Moser RP. Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue. J. Neuroimmunol. 57, 143-153 (1995).
59. Gladson CL Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors. J. Neuropathol. Exp. Neurol. 55, 1143-1149, (1996).
60. Mas-Moruno C, Rechenmacher F, Kessler H. Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med. Chem. 10(10), 753-768 (2010).
61. Reardon DA, Neyns B,Weller M, Tonn JC, Nabors LB, Stupp R. Cilengitide: an RGD pentapeptide anb3 and anb5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncol. 7(3), 339-354 (2011).
62. Reardon DA, Cheresh D. Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies. Genes Cancer 2(12), 1159-1165 (2011).
63. Hardee ME, Zagzag D. Mechanisms of glioma-associated neovascularization. Am. J. Pathol. 181(4), 1126-1141 Review (2012).
64. Eke I, Deuse Y, Hehlgans S et al. b1Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy. J. Clin. Invest. 122(4), 1529-1540 (2012).
65. Sandfort V, Koch U, Cordes N. Cell adhesion-mediated radioresistance revisited. Int. J. Radiat. Biol. 83(11-12), 727-732 (2007).
66. Maurer GD, Tritschler I, Adams B, Tabatabai G, Wick W, Stupp R, Weller M. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro Oncol. 11(6), 747-756 (2009).
67. Nabors LB, Mikkelsen T, Rosenfeld SS et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J. Clin. Oncol. 25(13), 1651-1657 (2007).
68. MacDonald TJ, Stewart CF, Kocak M et al. Phase I clinical trial of cilengitide in children with refractory brain tumors: pediatric brain tumor consortium study PBTC-012. J. Clin. Oncol. 26(6), 919-24 (2008).
69. Scaringi C, Minniti G, Caporello P, Enrici RM. Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. Anticancer Res. 32(10), 4213-4223 (2012).
70. Stupp R, Hegi ME, Mason WP et al; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5), 459-466 (2009).
71. Gorlia T, van den Bent MJ, Hegi ME et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 9(1), 29-38 (2008).
72. Stupp R, Hegi ME, Neyns B et al. Phase I/ IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28, 2712-2718 (2010).
73. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352(10), 997-1003 (2005).
74. Nabors LB, Mikkelsen T, Batchelor T et al. NABTT 0306: A randomized phase II trial of EMD 121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM). J. Clin. Oncol. 27, 15s Abstract 2001 (2009).
75. Blanchard P, Baujat B, Holostenco V et al. MACH-CH Collaborative group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother. Oncol. 100(1), 33-40 (2011).
76. Psyrri A, Sasaki C, Vassilakopoulou M, Dimitriadis G, Rampias T. Future directions in research, treatment and prevention of HPV-related squamous cell carcinoma of the head and neck. Head Neck Pathol. 6(Suppl. 1), S121-S128 (2012).
77. Schettino C, Bareschino MA, Sacco PC et al. New molecular targets in the treatment of NSCLC. Curr. Pharm. Des. 19(30), 5333-5343 (2013).
78. Pirker R, Filipits M. Monoclonal antibodies against EGFR in non-small cell lung cancer. Crit. Rev. Oncol. Hematol. 80(1), 1-9 (2011).
79. Laurie SA, Goss GD. Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer. J. Clin. Oncol. 31(8), 1061-1069 (2013).
80. Gatzemeier U, von Pawel J, Vynnychenko I et al. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: A subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol. 12, 30-37 (2011).
81. Lee HL, Chung TS, Ting LL et al. EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases. Radiat Oncol. 7, 181 (2012).
82. Bernier J, Cooper JS, Pajak TF et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 27(10), 843-850 (2005).
83. Sperduto PW, Wang M, Robins HI et al. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int. J. Radiat. Oncol. Biol. Phys. 85, 1312-1318 (2013).
84. Good JS, Harrington KJ. The hallmarks of cancer and the radiation oncologist: updating the 5rs of radiobiology. Clin. Oncol. 25(10), 569-577 (2013).
85. Russell JS, Brown JM. The irradiated tumor microenvironment: role of tumor-associated macrophages in vascular recovery. Front Physiol. 4, 157 (2013).
86. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat. Rev. Cancer 11(4), 239-253. Review (2011).